• 原料直供
• 试剂商城
• 直接询价

分类

• {SA} Antitumor Agents, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cancer Research, Cell Biology, Cell Signaling and Neuroscience, Cytokines, Growth Factors and Hormones, Danco Laboratories, Gene Regulation,
• Antitumor Agents, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cancer Research, Cell Biology, Cell Signaling and Neuroscience, Cytokines, Growth Factors and Hormones, Danco Laboratories, Gene Regulation, Hormones, M, Other Steroid Products, Progesterone Modulators, Steroid Hormones, Tumor Growth Regulation

产品应用

• Mifepristone is a synthetic steroid compound used as a pharmaceutical. It is used as an abortifacient in the first two months of pregnancy, and in smaller doses as an emergency contraceptive. During early trials, it was known as RU-486, its designation at the Roussel Uclaf company, which designed the drug. The drug was initially made available in France, and other countries then followed—often amid controversy. It is marketed under tradenames Mifegyne and Mifeprex.

相关文献及参考

• [2]. Jurado R, et al. NSC 119875 cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep. 2009 Nov;22(5):1237-45.
• [3]. Sharrett-Field L, et al. Mifepristone Pretreatment Reduces Ethanol Withdrawal Severity In Vivo. Alcohol Clin Exp Res. 2013 Aug;37(8):1417-23.
• [4]. Yuehua You, et al. Progesterone Promotes Endothelial Nitric Oxide Synthase Expression Through Enhancing Nuclear Progesterone receptor-SP1 Formation. Am J Physiol Heart Circ Physiol. 2020 Jul 3.
• Lecureur, V., et al., The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 355 , 187-194, (1994) 摘要
• Lucci, A., et al., Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int. J. Oncol. 15 , 535-540, (1999) 摘要
• Merchant, S., et al., Expression Of Complement And Pentraxin Proteins In Acute Phase

安全信息

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE                    : 12 mg/kg
SEX/DURATION            : female 6 week(s) after conception
TOXIC EFFECTS :
   Reproductive - Fertility - abortion
REFERENCE :
   EOGRAL European Journal of Obstetrics, Gynecology and Reproductive Biology.
   (Elsevier Science Pub. BV, POB 211, 1000 AE Amsterdam, Netherlands)  V.3-
   1973-  Volume(issue)/page/year: 28,249,1988

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Administration onto the skin
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 50 mg/kg
SEX/DURATION            : female 21 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Maternal Effects - parturition
   Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4
   per # born alive)
   Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight
   gain)
REFERENCE :
   JRPFA4 Journal of Reproduction and Fertility.  (Biochemical Soc. Book Depot,
   POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK)  V.1-    1960-
   Volume(issue)/page/year: 79,1,1987

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE                    : 12 mg/kg
SEX/DURATION            : female 10 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Fertility - abortion
REFERENCE :
   OBGNAS Obstetrics and Gynecology.  (Elsevier Science Pub. Co., Inc., 52
   Vanderbilt Ave., New York, NY 10017)  V.1-    1953- Volume(issue)/page/year:
   74,653,1989

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 30 mg/kg
SEX/DURATION            : female 2 day(s) after conception
TOXIC E